# Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration

> **NCT06223074** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Universidad Nacional Autonoma de Mexico** · enrollment: 80 (estimated)

## Conditions studied

- Multiple Sclerosis Relapsing Remitting
- Treatment

## Interventions

- **OTHER:** IV Methylprednisolone administration
- **DRUG:** Nasal Methylprednisolone (MT)

## Key facts

- **NCT ID:** NCT06223074
- **Lead sponsor:** Universidad Nacional Autonoma de Mexico
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-01-09
- **Primary completion:** 2026-02-25
- **Final completion:** 2026-07-05
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-04-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06223074

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06223074, "Improving the Treatment of Acute Relapses in Multiple Sclerosis Through Intranasal Methylprednisolone Administration". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06223074. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*